Jump to content

Opsona Therapeutics

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by TAnthony (talk | contribs) at 01:55, 12 August 2016 (top: USA is deprecated, per MOS:NOTUSA, and correct overlinking of common places using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Opsona Therapeutics
Founded1 January 2004 Edit this on Wikidata
Headquarters,
Republic of Ireland Edit this on Wikidata
Websitewww.opsona.com

Opsona Therapeutics is a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases.[1][2][3]

Based in Ireland, Opsona is a spin-out from Trinity College Dublin (TCD).[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field.[5]

Opsona's research is primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:

Opsona's main investors are international and life-science focused:

  • Inventages Venture Capital (Bahamas)[9]
  • Seroba Bioventures (Ireland)
  • GenenFund (United States)
  • Enterprise Ireland (Ireland)[10]

References